PA8800501A1 - Productos quimioterapeuticos cristalinos - Google Patents

Productos quimioterapeuticos cristalinos

Info

Publication number
PA8800501A1
PA8800501A1 PA20088800501A PA8800501A PA8800501A1 PA 8800501 A1 PA8800501 A1 PA 8800501A1 PA 20088800501 A PA20088800501 A PA 20088800501A PA 8800501 A PA8800501 A PA 8800501A PA 8800501 A1 PA8800501 A1 PA 8800501A1
Authority
PA
Panama
Prior art keywords
crystal
chemotherapeutic products
chemotherapeutic
products
ways
Prior art date
Application number
PA20088800501A
Other languages
English (en)
Inventor
F Henry Rodger
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of PA8800501A1 publication Critical patent/PA8800501A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

FORMA CRISTALINA 1 DE N-(4-(3-AMINO-1H-INDAZOL-4-IL)FENIL)-N'-(2-FLUORO-5-METILFENIL)UREA TOLUENATO, MANERAS PARA ELABORARLA Y FORMAS DE USARLA.
PA20088800501A 2007-10-19 2008-10-17 Productos quimioterapeuticos cristalinos PA8800501A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98124307P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
PA8800501A1 true PA8800501A1 (es) 2009-05-15

Family

ID=40242659

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088800501A PA8800501A1 (es) 2007-10-19 2008-10-17 Productos quimioterapeuticos cristalinos

Country Status (20)

Country Link
US (1) US7943782B2 (es)
EP (1) EP2195297A1 (es)
JP (1) JP2011500706A (es)
KR (1) KR20100102098A (es)
CN (1) CN101827823B (es)
AU (1) AU2008312532A1 (es)
BR (1) BRPI0818343A2 (es)
CA (1) CA2699353A1 (es)
CO (1) CO6280483A2 (es)
CR (1) CR11386A (es)
DO (1) DOP2010000116A (es)
GT (1) GT201000101A (es)
MX (1) MX2010004289A (es)
MY (1) MY153098A (es)
PA (1) PA8800501A1 (es)
RU (1) RU2010119917A (es)
SG (1) SG185326A1 (es)
UA (1) UA99487C2 (es)
WO (1) WO2009052229A1 (es)
ZA (1) ZA201002092B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
JP2017524034A (ja) 2014-08-08 2017-08-24 フォーサイト・ビジョン フォー・インコーポレーテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ４， Ｉｎｃ． 受容体型チロシンキナーゼ阻害剤の安定で可溶な製剤およびその調製の方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL373788A1 (en) * 2002-05-10 2005-09-19 Teva Pharmaceutical Industries Ltd. Novel crystalline forms of gatifloxacin
US7531551B2 (en) * 2003-05-08 2009-05-12 Ivax Pharmaceuticals S.R.O. Polymorphs of cabergoline
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
JP4810427B2 (ja) * 2003-05-22 2011-11-09 アボット・ラボラトリーズ インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤
DE102005033100B3 (de) * 2005-07-15 2007-01-25 Sanofi-Aventis Deutschland Gmbh Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung
US20100105031A1 (en) * 2005-08-01 2010-04-29 Esai R & D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
JP4989476B2 (ja) * 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
US20070104780A1 (en) 2005-10-25 2007-05-10 Lipari John M Formulation comprising a drug of low water solubility and method of use thereof
JP2009521493A (ja) * 2005-12-23 2009-06-04 アルコン，インコーポレイテッド 眼への受容体チロシンキナーゼ阻害（ＲＴＫｉ）化合物の送達のための医薬製剤
JP2009523806A (ja) * 2006-01-20 2009-06-25 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ （４ｒ）−１−［４−（２−クロロ−５−フルオロベンゾイル）アミノ−３−メトキシベンゾイル］−１，２，３，５−テトラヒドロ−スピロ［４ｈ−１−ベンズアゼピン−４，１’−［２］シクロペンテン］−３’−カルボン酸の新規固体形態物
EP2089003A1 (en) * 2006-11-09 2009-08-19 Abbott GmbH & Co. KG Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

Also Published As

Publication number Publication date
US7943782B2 (en) 2011-05-17
UA99487C2 (xx) 2012-08-27
MY153098A (en) 2014-12-31
ZA201002092B (en) 2011-11-30
AU2008312532A1 (en) 2009-04-23
CO6280483A2 (es) 2011-05-20
WO2009052229A1 (en) 2009-04-23
EP2195297A1 (en) 2010-06-16
RU2010119917A (ru) 2011-11-27
CN101827823A (zh) 2010-09-08
KR20100102098A (ko) 2010-09-20
CN101827823B (zh) 2012-10-03
US20090105486A1 (en) 2009-04-23
MX2010004289A (es) 2010-04-30
CA2699353A1 (en) 2009-04-23
CR11386A (es) 2010-08-18
JP2011500706A (ja) 2011-01-06
BRPI0818343A2 (pt) 2017-05-23
DOP2010000116A (es) 2010-05-31
GT201000101A (es) 2012-03-26
SG185326A1 (en) 2012-11-29

Similar Documents

Publication Publication Date Title
CR11416A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
EP1845086A4 (en) N-SUBSTITUTED N-METHOXYCARBAMATES BY 2-SUBSTITUTED PHENYL GROUPS, THEIR SYNTHESIS AND THEIR APPLICATIONS
HN2005000722A (es) Forma termodinamicamente estable de una sal tosilato
CY1109414T1 (el) Ν-σουλφονυλ πυρρολια και χρηση αυτων ως αναστολεις αποακετυλασης ιστονης
BR112012023525A2 (pt) método para preparar n-(4-cloro-3(triflúor metil)fenil)-n'-(4-(2-(n-(metil-d3)amino formil)-4-piridiloxi)fenil)uréia, intermediário, método para preparar 4-cloro-piridil-2-(n-(metil-d3))carboxamida, uso do intermediário e composto de ?-difenil uréia deuterada de p-tolueno sulfonato
PL2201018T3 (pl) STAŁE POSTACIE ZAWIERAJĄCE N-(5-TERT-BUTYLOIZOKSAZOL-3-ILO)-N'-{4--[7-(2-MORFOLIN-4-YLOETOKSY)IMIDAZO[2,1-b][1,3]BENZOTIAZOL-2-ILO]FENYLO}MOCZNIK, ICH KOMPOZYCJE ORAZ ICH ZASTOSOWANIA
DE602006009789D1 (de) Acetylenderivate
PA8800501A1 (es) Productos quimioterapeuticos cristalinos
GT201000100A (es) Productos quimioterapéuticos cristalinos
ECSP10010175A (es) Productos quimioterapéuticos cristalinos
CR20110082A (es) Nuevos inhibidores de la proteina tirosina quinasa y receptores vegf-2 y uso farmacéutico de los mismos
CL2008003091A1 (es) Forma cristalina 1 de etanolato de n-(4-(3-amino-1h-indazol-4il)fenil)-n-(2-fluoro-5-metilfenil)urea. 1/4; composicion farmaceutica; y uso en el tratamiento de cancer en un mamifero.
CY1110942T1 (el) Αλας αιθανολαμινης n-(3-μεθοξυ-αιθοξυ-5-μεθυλπυραζιν-2-υλ)-2-(4-[1,3,4-οξαδιαζολο -2-υλ]φαινυλ)πυριδινο-3-σουλφοναμιδιου
MX2017003916A (es) Forma de medicamento solido de clorhidrato de n-(2,6 bis (1 metiletil)fenil)-n'-((1-(4-(dimetilamino)fenil)ciclopentil) metil)urea y composiciones, metodos y kits relacionados con la misma.
ECSP10010177A (es) Productos quimioterapéuticos cristalinos
BRPI0818065A8 (pt) Quimioterapêutco derivado de indazol cristalino
AR052920A1 (es) Inhibidor de acat cristalino
ITRM20070018A1 (it) Sintesi del 2,5-diidrossitirosolo e suo uso
ES1064891Y (es) Pistola dosificadora para la aplicacion de mechas y tintes en el cabello
UA105062C2 (uk) Застосування n-(9-флуореніліден)-n'-ацетогідразиду як протитуберкульозного засобу
UA87361C2 (ru) КАЛИЙ N-(9-ФЛУОРЕНИЛИДЕН)-N'-м-АНИСОГИДРАЗОНАТ, КОТОРЫЙ ПРОЯВЛЯЕТ ПРОТИВОТУБЕРКУЛЕЗНОЕ ДЕЙСТВИЕ